AU2009299615B2 - Anthrax vaccine formulation and uses thereof - Google Patents

Anthrax vaccine formulation and uses thereof Download PDF

Info

Publication number
AU2009299615B2
AU2009299615B2 AU2009299615A AU2009299615A AU2009299615B2 AU 2009299615 B2 AU2009299615 B2 AU 2009299615B2 AU 2009299615 A AU2009299615 A AU 2009299615A AU 2009299615 A AU2009299615 A AU 2009299615A AU 2009299615 B2 AU2009299615 B2 AU 2009299615B2
Authority
AU
Australia
Prior art keywords
rpa
phosphate
vaccine
anthrax
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009299615A
Other languages
English (en)
Other versions
AU2009299615A1 (en
Inventor
Allan Watkinson
Robert Wilson
David Woodhouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune Inc
Original Assignee
Pharmathene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathene Inc filed Critical Pharmathene Inc
Publication of AU2009299615A1 publication Critical patent/AU2009299615A1/en
Application granted granted Critical
Publication of AU2009299615B2 publication Critical patent/AU2009299615B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2009299615A 2008-10-02 2009-10-02 Anthrax vaccine formulation and uses thereof Ceased AU2009299615B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19496708P 2008-10-02 2008-10-02
US61/194,967 2008-10-02
PCT/GB2009/051293 WO2010038076A1 (en) 2008-10-02 2009-10-02 Anthrax vaccine formulation and uses thereof

Publications (2)

Publication Number Publication Date
AU2009299615A1 AU2009299615A1 (en) 2010-04-08
AU2009299615B2 true AU2009299615B2 (en) 2015-07-16

Family

ID=41292568

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009299615A Ceased AU2009299615B2 (en) 2008-10-02 2009-10-02 Anthrax vaccine formulation and uses thereof

Country Status (7)

Country Link
US (1) US9616117B2 (enExample)
EP (1) EP2344188B1 (enExample)
JP (1) JP5701760B2 (enExample)
AU (1) AU2009299615B2 (enExample)
CA (1) CA2738621C (enExample)
IL (1) IL212118A (enExample)
WO (1) WO2010038076A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093072A1 (en) * 2008-01-22 2009-07-30 Pharmathene Uk Limited Vaccine composition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) * 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
DE2632478A1 (de) 1975-07-23 1977-02-24 Coulter Electronics Verfahren zur erfassung und trennung von antigenen und antikoerperchen im blut und in anderen proben
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US5690942A (en) 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9618107D0 (en) 1996-08-30 1996-10-09 Secr Defence Vaccine production
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
KR20030020294A (ko) 2000-06-08 2003-03-08 파우더젝트 백신, 인코포레이티드 분말 조성물
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
WO2002100340A2 (en) 2001-06-08 2002-12-19 Avant Immunotherapeutics, Inc. Improved vaccination against anthrax
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0126266D0 (en) * 2001-11-01 2002-01-02 Microbiological Res Authority Anthrax antigenic compositions
UA80809C2 (en) 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
US7888490B2 (en) 2001-12-05 2011-02-15 Centre of Biotechnology Jawaharlal Nehru University Process for the preparation of non-toxic anthrax vaccine
ATE503491T1 (de) 2003-02-13 2011-04-15 Becton Dickinson Co Verbesserte anthraximpfstoffe und abgabeverfahren
EP1755677A4 (en) 2004-06-14 2009-11-25 Medimmune Vaccines Inc HIGH-PRESSURE SPRAY DRYING OF BIOACTIVE MATERIALS
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
JP2008514644A (ja) 2004-09-28 2008-05-08 アルザ コーポレイション ミョウバンアジュバント免疫活性剤の安定化
GB0525213D0 (en) 2005-12-12 2006-01-18 Secr Defence Vaccine
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
GB0607462D0 (en) 2006-04-13 2006-05-24 Avecia Ltd Assay
JP2010502747A (ja) 2006-09-08 2010-01-28 ベクトン・ディキンソン・アンド・カンパニー ミョウバン吸着ワクチンの安定粉末製剤
EP1972347A1 (en) 2007-03-19 2008-09-24 Becton, Dickinson and Company, Wagner, Jaconda Stable vaccine powder formulations
WO2008152654A1 (en) 2007-06-11 2008-12-18 Panacea Biotec Limited Anthrax fusion proteins, compositions and uses thereof
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2010084298A1 (en) 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093072A1 (en) * 2008-01-22 2009-07-30 Pharmathene Uk Limited Vaccine composition

Also Published As

Publication number Publication date
WO2010038076A1 (en) 2010-04-08
CA2738621A1 (en) 2010-04-08
JP5701760B2 (ja) 2015-04-15
US20110236425A1 (en) 2011-09-29
IL212118A0 (en) 2011-07-31
EP2344188B1 (en) 2017-02-15
AU2009299615A1 (en) 2010-04-08
JP2012504589A (ja) 2012-02-23
IL212118A (en) 2017-03-30
EP2344188A1 (en) 2011-07-20
CA2738621C (en) 2017-01-31
US9616117B2 (en) 2017-04-11

Similar Documents

Publication Publication Date Title
JP6438599B2 (ja) 抗ｃｇｒｐ抗体製剤
US7993648B2 (en) Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
US7504107B2 (en) Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response
CN116023510B (zh) 双佐剂重组带状疱疹疫苗
JP5745577B2 (ja) Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
CN103906760B (zh) 用作抗原掩蔽剂的人乳铁蛋白衍生肽
CA2738621C (en) Anthrax vaccine formulation and uses thereof
CN101478987A (zh) 含有单克隆抗独特型抗ca-125抗体和铝的药物组合物
WO2024148364A1 (en) Intertumoral and intratumoral delivery of cytokines using mesoporous silica rods as an immunomodulating system
HK40124168A (zh) 使用抗fcrn抗体治疗格雷夫斯病的方法
TW202203970A (zh) 靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法
WO2024254149A2 (en) Virus-inspired compositions comprising virus-like proteins and checkpoint inhibitors, and methods of use thereof to treat cancer
HK40121539A (zh) 使用抗fcrn抗体治疗慢性炎性脱髓鞘性多发性神经病的方法
MX2013006501A (es) Vacuna fuertemente inactivada y todavia sumamente inmunogenica, y proceso para su fabricacion.
HK1196379B (en) Human lactoferrin derived peptide for use as an antigen masking agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired